Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

StiffMAP-HFpEF trial is an investigator initiated, observational, single-center study that will evaluate whether fibrosis quantification by cardiac MRI correlates with left and right ventricular stiffness derived from pressure-volume analysis, aiming to clarify if cardiac MRI is a valid, non-invasive method to assess diastolic function in patients with Heart Failure with preserved ejection fraction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CMR Assessment of Cardiac Microvascular Dysfunction in Patients With HFpEF

NCT06316661

Microvascular Coronary Artery Disease Heart Failure With Reduced Ejection Fraction

RECRUITING

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

NCT07178145

Heart Failure Preserved Ejection Fraction Epicardial Adipose Tissue

NOT_YET_RECRUITING PHASE4

The Prognostic Role of the Right Ventricle in Patients With Heart Failure or Congenital Heart Disease

NCT03969394

Heart Failure

UNKNOWN NA

Cardiac MRI-Derived Pressure-Volume Loop Analysis in Heart Failure With Preserved Ejection Fraction

NCT07326605

Heart Failure With Preserved Ejection Fraction (HFPEF)

ENROLLING_BY_INVITATION

T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease

NCT02350829

Cardiomyopathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart Failure with preserved ejection fraction (HFpEF) and diastolic dysfunction is a growing medical challenge. To date almost every second patient with heart failure has a preserved ejection fraction and recent data show that outcomes in these patients are as bad as in those with reduced ejection fraction. In clinical routine the diagnosis of HFpEF is complicated by indirect assessment of diastolic function. Mechanistically the diastolic dysfunction is among others believed to be caused by the development of diffuse myocardial fibrosis with an increase of extracellular matrix.

Direct assessment of the intrinsic diastolic function and stiffness of the ventricle can be obtained by pressure-volume-curve tracings through a conductance catheter. Although this offers the benefit of assessing load-dependent and load-independent parameters of diastolic function as well as information on contractility and ventricular-arterial coupling, the use of this technique is limited by its invasiveness in daily care.

Newer MRI techniques have made it possible to quantify not only local fibrosis but also diffuse fibrosis (i.e. T1-Mapping) and determine extracellular volumes.

Moreover, the role of right ventricular function is in HFpEF is not well defined.

Aim of the current study is therefore to evaluate the role of MRI in assessing cardiac fibrosis in the context of impaired LV diastolic function in HFpEF patients, as well as to evaluate the role of systolic and diastolic right ventricular functional impairment in this patient cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Normal Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HFpEF and servere diastolic dysfuntion

Left ventricular ejection fraction (LV-EF) \> 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=\>2, Diagnostic P-V-loops and MRI

Diagnostic P-V-loops and MRI

Intervention Type OTHER

Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

HFpEF no servere diastolic dysfuntion

LV-EF \> 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=\>2, Diagnostic P-V-loops and MRI

Diagnostic P-V-loops and MRI

Intervention Type OTHER

Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

No HF or diastolic dysfunction

LV-EF \> 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI

Diagnostic P-V-loops and MRI

Intervention Type OTHER

Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diagnostic P-V-loops and MRI

Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LV-EF \> 50%
* Indication for invasive cardiac catheterization

Exclusion Criteria

* know CAD or CAD in Angiography (stenoses \> 50%)
* acute coronary syndromes
* Cerebral ischemia within the last year
* contraindications for MRI
* more than mild valvular disease
* Constrictive pericarditis, restrictive Cardiomyopathy, pericardial effusion
* pregnancy
* enrolment in other study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No